Is Tricuspid Regurgitation after TAVR Significant?

Courtesy of Dr. Carlos Fava.

Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution.

Más coincidencias de las esperadas entre válvulas bicúspides y tricúspidesA meta-analysis of 12 studies with a total 41485 patients was carried out.

 

Early mortality (up to 6 months) was 1.8 times higher with severe or ≥moderate tricuspid regurgitation (OR, 1.80; 95% CI, 1.01 to 3.19; P=0.05). Between 6 and 30 months after TAVR, it was 1.9 times higher (HR/OR, 1.96; 95% CI, 1.35 to 2.85; P = 0.0004).


Read also: ¿Metformin to Treat Abdominal Aortic Aneurysms?


A second meta-analysis of 7 homogeneous studies was carried out and mortality between 6 and 30 months was 2.25 times higher (HR,2.25; 95% CI, 1.20–4.24; P= 0.01).

 

Conclusion

Significant tricuspid regurgitation (severe or ≥moderate) is associated to an approximate two-fold increase in early or mid-term all-cause mortality in patients with aortic stenosis undergoing TAVR.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation.

Reference: Hisato Takagi, et al. Catheter Cardiovasc Interv. 2018;1–8. DOI: 10.1002/ccd.27948.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...